<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02348450</url>
  </required_header>
  <id_info>
    <org_study_id>CTONG1404</org_study_id>
    <nct_id>NCT02348450</nct_id>
  </id_info>
  <brief_title>Irinotecan Plus Cisplatin Compared With Etoposide Plus Cisplatin for Extensive Stage Small-cell Lung Cancer</brief_title>
  <official_title>Irinotecan Plus Cisplatin Compared With Etoposide Plus Cisplatin for Extensive Stage Small-cell Lung Cancer: a Multi-center, Randomized, Open Label Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guangdong Association of Clinical Trials</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guangdong Association of Clinical Trials</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is aimed to evaluate the progression-free survival(PFS) and also survival of IP
      and EP (head-to-head) as the first line therapy for extensive stage small-cell lung cancer
      and to explore the reasonable first-line therapy for Chinese population. An open-label,
      multi-center study will be conducted with dynamic randomization of approximately 1:1 ratio
      with an estimation of 308 eligible participants.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      evaluate the progression-free survival(PFS) and also survival of IP and EP (head-to-head) as
      the first line therapy for extensive stage small-cell lung cancer and to explore the
      reasonable first-line therapy for Chinese population.

      An open-label, multi-center study will be conducted with dynamic randomization of
      approximately 1:1 ratio with an estimation of 308 eligible participants.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">February 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival of first line therapy</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients experience adverse events</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival of second line therapy</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">308</enrollment>
  <condition>Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Irinotecan plus Cisplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>first line: irinotecan 65mg/m2 d1,8. Cisplatin 30mg/m2，d1,8, 21days/cycle×6 cycles Second-line: etoposide alone OR etoposide plus cisplatin, dosage will be same as first line or on investigator's discretion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Etoposide plus Cisplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>first line: etoposide 60mg/m2 d1-5 Cisplatin 75mg/m2，d1(recommended), or administer three times with same total daily dose , 21days/cycle×6 cycles Second-line: irinotecan alone or irinotecan plus cisplatin, dosage is same as first line or on investigator's discretion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <description>40mg</description>
    <arm_group_label>Irinotecan plus Cisplatin</arm_group_label>
    <other_name>Ai Li</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>5ml：0.1g</description>
    <arm_group_label>Etoposide plus Cisplatin</arm_group_label>
    <other_name>H32025583</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>6ml：30mg</description>
    <arm_group_label>Irinotecan plus Cisplatin</arm_group_label>
    <arm_group_label>Etoposide plus Cisplatin</arm_group_label>
    <other_name>Nuo Xin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cytologically or histologically confirmed extensive stage small-cell lung cancer
             (remote metastasis and/or contralateral lymph-node involvement; not those with simple
             ipsilateral pleural effusion);

          -  No prior radiotherapy, chemotherapy or surgery;

          -  At least one measurable lesion, CT≥20mm, spiral CT≥10mm(diameter);

          -  ECOG PS 0-1;

          -  Age 18-70;

          -  Life expectancy &gt; three months;

          -  In general normal function of heart, liver, kidney and bone marrow;

          -  WBC C＞4.0×10(9)/L, NEUT＞1.50×10(9)/L, PLT＞100×10(9)/L, Hb＞95g/L;

          -  Liver function: TBIL &lt; 1.5 x UL normal range; ALT and AST &lt; 1.5 x UL normal range;

          -  Kidney function: normal serum creatinine level;

          -  Signed an informed consent and will comply with the study protocol and follow-up
             plans.

        Exclusion Criteria:

          -  Failed to meet the entry criteria of pathology and clinical stage;

          -  Have received prior chemotherapy or target treatment;

          -  Currently receiving other anticancer therapy;

          -  No measurable lesions or lesions cannot be assessed;

          -  Patients with acute or chronic medical or psychiatric condition, or laboratory
             abnormalities that may impact the judgment of the investigator and the result of the
             study, determined by investigator they may include:

        Uncontrolled tumor metastasis in central nerve system; Uncontrolled hypertension, unstable
        angina, MI history, or congestive heart-failure, uncontrolled arrhythmia, ischemic vascular
        disease within the 12 months prior to study treatment; Myocardial ischemia by ECG or
        valvular heart disease; Grade 3 or above peripheral neuropathy; Active stage of infection
        by bacteria, fungi or virus; Pregnant or breast feeding woman; History of uncontrolled
        mental disease.

          -  Not able to discontinue NSAIDs treatment;

          -  Other active malignant tumors except non-melanoma skin cancer, in-situ cervical
             carcinoma and cured early prostatic carcinoma;

          -  Patients with allergies, known or may be allergic to drugs in research;

          -  Patients with poor compliance to treatment and follow-up;

          -  Patients with UGT1A1-6 and UGT1A1-28 gene mutation;

          -  With clinical symptoms of brain metastasis(patient with stable clinical performance
             and no need to treat can be included in the trial);

          -  Chest, abdominal or pericardial effusion that needs anti-cancer intervention;

          -  Accompanied with Grade ≥2 diarrhea;

          -  Participated in other clinical trials within one month before randomization;

          -  Investigator's judgment to exclude.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shun Lu, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Chest hospital of Shanghai Jiaotong University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shun Lu, M.D</last_name>
    <phone>86-13601813062</phone>
    <email>shun_lu@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>zhiwei Chen</last_name>
    <phone>86-13916251926</phone>
    <email>drchenzhiwei@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The First Affiliated Hospital of AnHui Medical University</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>yueyin pan</last_name>
      <phone>86-13805695536</phone>
      <email>yueyinpan@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>wei huang</last_name>
      <phone>86-13505514938</phone>
      <email>huangweibsh@163.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>FuJian Provincial Tumor Hospital</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>cheng huang</last_name>
      <phone>13905010379</phone>
      <email>cheng671@sina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Guangdong General Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cancer Hospital Affiliated To GuangXi Medical University</name>
      <address>
        <city>Nanning</city>
        <state>Guangxi</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>xiangqun song</last_name>
      <phone>86-13877104657</phone>
      <email>xiangquns@163.com</email>
    </contact>
    <contact_backup>
      <last_name>shaozhang zhou</last_name>
      <phone>86-18677115144</phone>
      <email>zhoushaozhang@qq.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Fourth hospital of hebei medical university</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>cuimin ding</last_name>
      <phone>86-13933083069</phone>
      <email>wjwdcm@sina.com</email>
    </contact>
    <contact_backup>
      <last_name>ruijuan li</last_name>
      <phone>86-18231196950</phone>
      <email>lrj0310@sina.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of HaErBin Medical University</name>
      <address>
        <city>Haerbin</city>
        <state>Heilongjiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>gongyan chen</last_name>
    </contact>
    <contact_backup>
      <last_name>xuan hong</last_name>
      <phone>13946066560</phone>
      <email>hongxuan_1218@sina.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>HeNan Provincial Tumor Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>zhiyong Ma</last_name>
    </contact>
    <contact_backup>
      <last_name>xiangtao Yan</last_name>
      <phone>18638628118</phone>
      <email>skyliuyun@126.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>WuHan Tongji Hospital</name>
      <address>
        <city>WuHan</city>
        <state>Hubei</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>yuan chen</last_name>
    </contact>
    <contact_backup>
      <last_name>qian chu</last_name>
      <email>qianchu@tjh.tjmu.edu.cn</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>HuNan Provincial Tumor Hospital</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>jianhua chen</last_name>
    </contact>
    <contact_backup>
      <last_name>yongzhong luo</last_name>
      <phone>13607443876</phone>
      <email>65523714@qq.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>JiangSu Provincial Tumor Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>meiqi shi</last_name>
      <phone>13809029766</phone>
      <email>shimeiqi1963@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of NanChang University</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>LiaoNing Provincial Tumor Hospital</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>ShanDong Provincial Tumor Hospital</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>qisen guo</last_name>
    </contact>
    <contact_backup>
      <last_name>yan guan</last_name>
      <phone>15865298279</phone>
      <email>qhgy219@163.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Linyi cancer hospital</name>
      <address>
        <city>Linyi</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>jianhua shi</last_name>
      <phone>86-15963998868</phone>
      <email>shijianhualy@126.com</email>
    </contact>
    <contact_backup>
      <last_name>shuoxin liu</last_name>
      <phone>86-15969916696</phone>
      <email>lyzlyygcp@163.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Changhai Hospital of Shanghai</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>chong bai</last_name>
    </contact>
    <contact_backup>
      <last_name>huijie zhang</last_name>
      <phone>18621775835</phone>
      <email>15236196601@163.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>East Hospital Affiliated To Tongji University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shanghai Chest hospital of Shanghai Jiaotong University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shun Lu, MD</last_name>
      <phone>86 13601813062</phone>
      <email>shun_lu@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Zhiwei Chen</last_name>
      <phone>86 13916251926</phone>
      <email>drchenzhiwei@163.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hangzhou First People's Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>The second affiliated hospital of zhejiang university school of medicine</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>kai wang</last_name>
      <phone>86-13957158572</phone>
      <email>doctorhuxi@163.com</email>
    </contact>
    <contact_backup>
      <last_name>liren ding</last_name>
      <phone>86-13906535702</phone>
      <email>lirending@zju.edu.cn</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>ZheJiang Provincial Tumor Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 23, 2014</study_first_submitted>
  <study_first_submitted_qc>January 22, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2015</study_first_posted>
  <last_update_submitted>December 2, 2016</last_update_submitted>
  <last_update_submitted_qc>December 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 5, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Camptothecin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

